The company's subordinate enterprises are located in Beijing, Shanghai, Nanjing, Lianyungang, Qingdao and other places, and have multiple manufacturing sites.
CTTQ is the largest subsidiary of Sino Biopharm and one of the largest prescription drug manufacturer in China, which specializes in the therapeutic areas of oncology, hepatology and respiratory. Its major products include Anlotinib, Tianqingganmei and Penpulimab.
Beijing Tide is a subsidiary of Sino Biopharm in partner with China-Japan Friendship Hospital, which specializes in the therapeutic areas of respiratory and surgery/analgesic. Its major products include Flurbiprofen Cataplasm, Flurbiprofen Injection and Beraprost.
invoX is a wholly owned subsidiary of Sino Biopharm headquartered in London, UK. Through three strategic acquisitions of F-star, pHion, and Softhale, invoX has established a strong R&D platform across bispecific antibody, mRNA delivery system, and soft mist inhalation. invoX will focus on R&D and business development activities outside of China, with a core focus on oncology and respiratory therapeutics.
